Clinical Trial Update: Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

A Phase 3 study assessing the safety and efficacy of somatropin in children with growth hormone deficiency has been completed. The sponsor is Novo Nordisk A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency
• Growth Hormone Deficiency in Children

Drugs mentioned

• Norditropin (somatropin)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 3 | Status: COMPLETED